DURECT Corp (DRRX):企業の財務・戦略的SWOT分析

◆英語タイトル:DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME305FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

DURECT Corp (DRRX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

DURECT Corp (Durect) is a biopharmaceutical company that focuses on research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. It also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.

DURECT Corp Key Recent Developments

Mar 05,2021: DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Feb 25,2021: DURECT to Announce 2020 Financial Results and Provide Business Update on March 4
Jan 04,2021: DURECT announces closing of LACTEL Absorbable Polymer Product Line sale to Evonik and receipt of $15 million
Nov 02,2020: DURECT announces third quarter 2020 financial results and update of programs
Nov 02,2020: DURECT appoints Dr. Norman Sussman as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
DURECT Corp – Key Facts
DURECT Corp – Key Employees
DURECT Corp – Key Employee Biographies
DURECT Corp – Major Products and Services
DURECT Corp – History
DURECT Corp – Company Statement
DURECT Corp – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
DURECT Corp – Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
DURECT Corp – Corporate Strategy
DURECT Corp – SWOT Analysis
SWOT Analysis – Overview
DURECT Corp – Strengths
DURECT Corp – Weaknesses
DURECT Corp – Opportunities
DURECT Corp – Threats
DURECT Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
DURECT Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 05, 2021: DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Feb 25, 2021: DURECT to Announce 2020 Financial Results and Provide Business Update on March 4
Nov 02, 2020: DURECT announces third quarter 2020 financial results and update of programs
Nov 02, 2020: DURECT appoints Dr. Norman Sussman as Chief Medical Officer
Aug 03, 2020: DURECT announces second quarter 2020 financial results and update of programs
May 12, 2020: DURECT announces first quarter 2020 financial results and update of programs
May 05, 2020: DURECT receives loan under Paycheck Protection Program
Mar 03, 2020: DURECT announces fourth quarter and full year 2019 financial results and update of programs
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
DURECT Corp, Key Facts
DURECT Corp, Key Employees
DURECT Corp, Key Employee Biographies
DURECT Corp, Major Products and Services
DURECT Corp, History
DURECT Corp, Key Competitors
DURECT Corp, Ratios based on current share price
DURECT Corp, Annual Ratios
DURECT Corp, Annual Ratios (Cont...1)
DURECT Corp, Interim Ratios
DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
DURECT Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[DURECT Corp (DRRX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Neuraltus Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Neuraltus Pharmaceuticals Inc (Neuraltus) is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases. The company offers products under clinical development that include NP001 and others. Neuraltus’ focuses on macrophage which …
  • Compuware Corp:企業の戦略・SWOT・財務情報
    Compuware Corp - Strategy, SWOT and Corporate Finance Report Summary Compuware Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Double Bond Pharmaceutical International AB (DBPB):製薬・医療:M&Aディール及び事業提携情報
    Summary Double Bond Pharmaceutical International AB (DBP) is a pharmaceutical company that design, develop and commercialize therapies for cancer and autoimmune diseases. The company’s product pipeline includes SI-053 (Temodex), a novel therapy to treat malignant brain tumors; SA-033, SA-042, and SA …
  • Raymond James Financial Inc:戦略・SWOT・企業財務分析
    Raymond James Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Raymond James Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nayara Energy Ltd.:企業の戦略・SWOT・財務分析
    Nayara Energy Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nayara Energy Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • InCarda Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary InCarda Therapeutics Inc (InCarda) is a biopharmaceutical company that concentrates on the development of transformative therapies for cardiovascular conditions through the inhalation route. The company’s lead product candidate includes InRhythm, an inhaled antiarrhythmic for acute treatment …
  • Vericel Corp (VCEL)-医療機器分野:企業M&A・提携分析
    Summary Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell thera …
  • Tokyo Tatemono Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Tatemono Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Tatemono Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Franz Haniel & Cie. GmbH:企業の戦略・SWOT・財務情報
    Franz Haniel & Cie. GmbH - Strategy, SWOT and Corporate Finance Report Summary Franz Haniel & Cie. GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Willis Lease Finance Corp (WLFC)
    Willis Lease Finance Corp (WLFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • PT Mitra Adiperkasa Tbk:企業の戦略・SWOT・財務情報
    PT Mitra Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Mitra Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Cantel Medical Corp. (CMD)-医療機器分野:企業M&A・提携分析
    Summary Cantel Medical Corp. (Cantel) is a manufacturer and distributor of infection prevention and control products and services to the healthcare market. The company’s product portfolio includes water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reproc …
  • Petroleos Mexicanos:企業の戦略・SWOT・財務情報
    Petroleos Mexicanos - Strategy, SWOT and Corporate Finance Report Summary Petroleos Mexicanos - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychia …
  • Universal Biosensors Inc (UBI)-医療機器分野:企業M&A・提携分析
    Summary Universal Biosensors Inc (UBI) is a medical diagnostic company. The company researches, develops and manufactures in vitro diagnostic test devices that are used for professional and consumer point-of-care. The company is working with Siemens Healthcare to develop a range of products for the …
  • The Saudi Arabian Monetary Agency:企業の戦略的SWOT分析
    The Saudi Arabian Monetary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Reliance Communications Ltd (RCOM):企業の財務・戦略的SWOT分析
    Reliance Communications Ltd (RCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • AMCON Distributing Company:戦略・SWOT・企業財務分析
    AMCON Distributing Company - Strategy, SWOT and Corporate Finance Report Summary AMCON Distributing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Stellar Biotechnologies Inc (SBOT)-製薬・医療分野:企業M&A・提携分析
    Summary Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injecta …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆